Although the fusions can drive cancer via expression level changes when an oncogene is fused with a strong promoter such as TMPRSS2-ERG fusions in prostate cancer31, we find that the majority 19,911 of the 28,863 oncofusions are in-frame mutations between exonic regions of two protein coding genes. Here, TMPRSS2 is linked to cancer.